Company Filing History:
Years Active: 2018-2019
Title: Yingjian Bo: Innovator in PDE2 Inhibitors
Introduction
Yingjian Bo is a prominent inventor based in Beijing, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target phosphodiesterase 2 (PDE2). With a total of three patents to his name, his work focuses on therapeutic agents for various central nervous system disorders.
Latest Patents
Yingjian Bo's latest patents include innovative compounds that serve as PDE2 inhibitors. The first patent describes substituted triazolo bicyclic compounds that are useful for treating central nervous system disorders associated with PDE2. These compounds have potential applications in treating neurological and psychiatric disorders such as schizophrenia, psychosis, Parkinson's disease, and Huntington's disease. The second patent involves pyrimidinone amide compounds, which may also be effective as therapeutic agents for both central and peripheral disorders linked to PDE2. These compounds aim to address a range of conditions, including Alzheimer's, cognitive impairment, anxiety, and depression.
Career Highlights
Throughout his career, Yingjian Bo has worked with notable companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and MSD R&D Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Yingjian Bo has collaborated with esteemed colleagues in his field, including Dong-Ming Shen and Michael P. Dwyer. These partnerships have likely enhanced his research and development efforts, leading to impactful advancements in therapeutic agents.
Conclusion
Yingjian Bo is a distinguished inventor whose work in PDE2 inhibitors has the potential to transform the treatment landscape for various neurological and psychiatric disorders. His contributions to medicinal chemistry are noteworthy and continue to influence the field.